Épigénétique

Discover now how this controversial American millionaire managed to reverse his aging thanks to epigenetics! 

In this recent study, researchers at Northwestern Medicine have discovered that an epigenetic drug, tazemetostat, initially developed for blood cancers and rare sarcomas, shows promise in halting the growth of bladder cancer in mice. Unlike traditional tumor inhibition, this drug activates the immune system, marking a paradigm shift in treating one of the most common solid tumors. Lead author Joshua Meeks highlights the drug's unique mechanism and its potential to enhance survival in advanced bladder cancer. The study underscores the role of epigenetic therapy in bladder cancer, with tazemetostat now undergoing clinical trials for late-stage bladder cancer patients, offering a new avenue for effective treatment.

In the quest to understand the mysterious multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2, researchers have uncovered an epigenetic signature named EPIMISC. This signature, identified in a cohort study comparing healthy children, children with COVID-19 without MIS-C, and children with MIS-C, sheds light on the altered immune response and viral activity control implicated in MIS-C development.